Key result
Yangxinshi reverses glucose-induced cardiac fibroblast fibrosis by upregulating Cbl-b and inhibiting Smad signaling.
Why the study?
Cardiac fibrosis is a major myocardial change in diabetic cardiomyopathy, but the exact mechanism of the Chinese medicine formula Yangxinshi on cardiac fibrosis remains uncertain.
Yangxinshi shows potential to attenuate cardiac fibrosis in diabetic cardiomyopathy by regulating the CBL pathway and inhibiting TGF-β/Smads signaling.
Answers are grounded in this paper and cite their sources.
May warrant preclinical follow-up in diabetic cardiomyopathy models; leaves open clinical translation of CBL pathway effects.
Background. Cardiac fibrosis (CF) is major myocardial change in diabetic cardiomyopathy (DCM). Yangxinshi as a Chinese medicine formula is used to treat cardiovascular diseases. However, the exact effective mechanism of Yangxinshi on CF is still uncertain. Hence, based on the pharmacological network, predicting the active components, potential targets and pathways of Yangxinshi on diabetic fibrosis require to be further studied. Materials and Methods. By using Cytoscape 3.6.0 Bisogenet plug-in, the active components of Yangxinshi were obtained and screened through TCMSP, and the PPI network of DCM-CF was constructed and then screened by CytoNCA plug-in. GO analysis and KEGG pathway enrichment analysis were carried out by Cluego plug-in. Combined with the results of network pharmacological analysis, cells in vitro were performed to verify the CF stimulated with high glucose or intervence with Yangxinshi, and the expressions of Cbl-b, p-smad2, and α-SMA were detected. Results. Yangxinshi might play a key role in reversing cardiac fibrosis in individuals with DCM by regulating the signal pathway of CBL and promoted the expression of Cbl-b and inhibited the expression of p-smad2 and α-SMA, verifying some predictive work via network pharmacology. Conclusion. Based on network pharmacology, this study demonstrates that the beneficial effect of Yangxinshi on CF is related to the Cbl-b/smad2 pathway, providing an idea for the therapeutic effect of Yangxinshi on cardiac fibrosis in DCM.
No takes yet. Share an insight, caveat, or question.
Kuang et al. (2022) studied Cardiac fibrosis in diabetic cardiomyopathy. Yangxinshi vs. High glucose control group without Yangxinshi was evaluated on Expression of Cbl-b, p-smad2, and α-SMA (p=0.023). Yangxinshi reversed high glucose-induced fibrotic changes in primary cardiac fibroblasts by significantly promoting Cbl-b expression and inhibiting p-smad2 and α-SMA expression.
Synapse has enriched 10 related papers. Consider them for comparative context: